Loading...
Docoh

Blueprint Medicines (BPMC)

Participants
Kristin Hodous Senior Manager-Investor Relations
Jeff Albers Chief Executive Officer
Christy Rossi Chief Commercial Officer
Becker Hewes Chief Medical Officer
Mike Landsittel Chief Financial Officer
Salveen Richter Goldman Sachs
Marc Frahm Cowen
Dane Leone Raymond James
Reni Benjamin JMP Securities
Peter Lawson Barclays
David Lebowitz Morgan Stanley
Benjamin Kallo Baird
Michael Schmidt Guggenheim Partners
Andrew Berens SVB Leerink
Arlinda Lee Canaccord
Call transcript
Due to licensing restrictions, you must log in to view earnings call transcripts.
Operator

Good morning everyone. My name is Seth, and I will be your conference operator for today. At this time, I would like to welcome everyone to the Blueprint Medicines Second Quarter 2021 Financial Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. now floor will of Kristin I Medicines. Blueprint Instructions] hand to the Hodous [Operator ahead. go Please

Kristin Hodous

morning, operator. you, Medicines and Call. plan release, XXXX Blueprint everyone, topics the Second Financial a we This which Conference outlines Results discuss Thank Operating morning Quarter Good today. and to issued press we welcome to

Chief on reviewing Albers, our press to the going Chief Quarter Becker the XXXX access financial results. as business our Commercial website will progress; highlights; Officer can will Medicines' Medical Chief Chief by Landsittel, www.blueprintmedicines.com. as well provide discuss Jeff the Second Christy review update; section today, review of Rossi, Financial our commercial Mike slides quarter Executive recent will Officer You release, clinical our and that second a XXXX our at Officer Today our we'll will call, Hewes, be Blueprint Investors our Officer

like make Actual call everyone started, set or get remind of our those that forward-looking to implied we results by or the and events include in Factors of we statements from Risk will a uncertainties factors, differ any other could I those Before various result as forth materially including filings. expressed conference this forward-looking SEC would statements, section on risks, statements.

as any In disclaim forward-looking any views representing specifically upon this update should our addition, any only as date. on be to any We our not views forward-looking call, or as relied statements. represents statement made and of today obligation subsequent revise of

Jeff Albers. here's CEO, our Now,

Jeff Albers

leading quarter a laid which In performance. Thanks were, in XXXX, portfolio accelerate of with and culmination and systemic target. hard a rare ushering FDA advanced mastocytosis we advanced In the difficult hematologic of central offering driver work for patient for has example of disorders. was research the to to across The pipeline. achievement mastocytosis genetic with global promise and care to we've the in disease, expand of review our AYVAKIT cancer new With historically of good team today, the This second two, a and therapy three, make partnership strategic therapeutic for precision designed and in targeted decade the ambition, puts quarter a GAVRETO; to and Systemic out three company. inhibit first a to as June, their real strongest mutant potently SM. in a approval to to AYVAKIT nearly our them medical everyone. of patients therapy medicine pillars communities. priorities further clear of and of is a therapy and been morning position us the been made from selectively received of to we the and is a joining the people SM, era us one, the that driver significant for ever Kristin into or disease. these Blueprint AYVAKIT approval, the of we're DXXXV January, our the Thanks, clinic; the company next second single improve for progress our the advance precision lives Underlying world's treatment precision wave these US our with with adoption candidates KIT, of classic build

to and work will It's to of to aspects very being and into discuss the portfolio, six proof-of-concept across Becker now registration-enabling our trials progressing clinical rewarding independently Christy access as to as programs SM, globally realized In launch, important AYVAKIT call. the momentum treatment. will patient across and in seeing the As later deliver through partnerships. GAVRETO shortly, have all and our review of efficiencies momentum we early both particularly parallel identification encouraging to we're patients making we're see the or advanced drive through launch AYVAKIT we stage as studies. progress We

two is enabled product our revenue each launches two Blueprint cancer; promising cancer to BLUE-XXX and with and that cell EGFR-driven scientific Roche. the What's immunotherapy treatment-resistant of is for financial allow BLU benefit patients. collaboration and will could stream for our our important of lung discuss. under further across patients product deliver transformative continue meaningful number a business as need. candidates we CDKX clinical exciting MAPXKX non-small position SM; product we've of and XXX, as portfolio, these strong with purposeful efforts Underpinning candidates improved for our execution that, our bring developed Through a outcomes innovation commercial medical a non-advanced a diversified programs a large will Mike inhibitor mix Our and strengthen inhibitor; and for [Indiscernible] very collaborations, to significant

So efforts. Christy? I'll to that, over call update the commercial with provide to an on turn Christy our

Christy Rossi

morning $X.X million Good Jeff. of million net $X.X and of everyone. In we of million, $XX.X including GAVRETO. you, in sales Thank in quarter, generated revenue product sales the AYVAKIT second total

weeks, SM three second providing we key product SM all which off change the education, approval few enormous we with create and for of the patients. upon to The advanced realize AYVAKIT believe are few interest we seen SM. the just And already past came of priorities: and just weeks against half over announcing about AYVAKIT already Immediately in to our first the patients, United marked inflection we've point launch a potential and our and see health beginning request XX after start, seen and providers the ensuring our support. States. centers, a strong a of patients prescription from utilization of of a for executing disease lives high ago, we have identifying level approval. quarter hours we by approval, and target We to engagement care received XX% The now Blueprint best-in-class significant of living are patients

heard AYVAKIT providers on in we the clinical supporting from with community-based we've experience demand who profile from Importantly, and encouraged are been care significant differentiated also package data previous including have setting. health those seeing robust launch. the clinical We've by feedback the physicians, no

health the of for the to pleased advanced especially as were a patients. treatment SM hearing for see option NCCN AYVAKIT are SM. their We available standard this are new AYVAKIT We and the care have to agent preferred that the added guidelines of will providers in excited to set treatment advanced

a midostorin including suggest market being and potential Our indication SM the broadly advanced types, used AYVAKIT the early data growth patients no that, other patient therapy. therapies of switching is These promising with such and of across are time. of from Ascent demand, advanced for indicators prior patients breadth current as over

in in see as from initial label. are access, long as prescribed insight our the this and role revolutionizing execution in I'm have by for on are is prescriptions our come AYVAKIT previous more every these Payer indicators into to our appear strong to Leveraging launches, patients our indicated. patient, treated, support therapy As area. as policies access fast, to is payer the and gain treatment who line also goal initial and will well help was dynamics, the approval of We've existing have that more as patients be to patient and SM. we encouraged offering we to with with strong it early infrastructure been playing advanced remains thrilled early our paradigm. clinically continued expertise AYVAKIT quickly start

the incremental of as be of our recognized approval, it expect primary over we progress going SM with to our outside growth While and look in timing revenue forward. continuing because smaller AYVAKIT you potential a QX, part to advance GIST, US forward the was driver as blockbuster In watch. on I revenue the update I alpha anticipate We time. opportunity, view launches advance more of PDF the additional or SM we the growth of to a

turn Let to now GAVRETO. me

overall to new our share are well. XX% growing updated rate we new see RET starting overall RET now treatment this our good patient starts an ARROW exceeds as increased Growing on ASCO in year, setting. the following share steadily and response the study Since see continue We selective has patients, remains progress that in of encouraged XX%. a inhibitor key to of demand We uptick market an where included who the were inhibitor. from launch data showcased naive a in focus

the on to testing actionable broader aids biomarker at our increase and efforts compelling supporting data diagnosis. education multidisciplinary Continued GAVRETO, rates comprehensive clinical

milestone a partners QX. at reached with we our and Importantly, Roche of end Genentech the at

States, will be assume responsibility the Genentech sales and booking as now United Going GAVRETO, will forward result end-user distribution. with for in also a product

who growth our from will identified are expect partners the ongoing that are driven patients We and and in US Roche the drive the number launches our in treated United ongoing outside we revenue confident of by CStone. further of States, joint and growth efforts

to us with in AYVAKIT I starts I and turn will launch BLU-XXX prescriptions the expand through to wanted all we front call advanced of non-advanced hours back the and transform of of in system the I Becker, Before and SM, SM, the few to the of to opportunity disease. first within patients come with AYVAKIT development approval. which advanced our Earlier treatment over mentioned had a ongoing that, of

they we community. could more talk that, came The Becker clinical a multiple impact that, position This patients that to portfolio. there have to excited the identified. have of they like patients this were a us also acute, patient SM leadership center With SM not the turn we the in over As it our with treatment I had portfolio I told now call need best-in-class from in that happens, across our is built subtypes would of about PIONEER. about in demonstrates of first disease. advanced patients debilitating opportunity SM the non-advanced more And to partnership power for and request team to be with had interested enrolling the the

Becker Hewes

good morning, Thank everyone. Christy, you, and

trial PIONEER disease. with of start in Let's AYVAKIT non-advanced the

across well As into non-advanced this non-advanced and is over with XXX we the first to PIONEER large the patients. consistently, eager conducted patients. to of required has which two and our effort, patients XX celebrate a to comprises during site. with operational the treatment disease, phase we're study XX ever of also trial, screened In for global advanced nearly SM, expand activated overwhelming moderate-to-severe the countries impact global carefully transition sites majority sites we've SM, worked disease evaluable complex We've pandemic. part the especially in registrational of Davis approval

for in the enthusiasm As us reinforced the AYVAKIT's trial's recent and approval population. investigator the disease, of increased patient has breadth this has for need momentum with advanced and

screening Now, looking sites, line enrollment to forward we're as we've down regulatory data, efforts potential with mid-XXXX filings in driving thereafter. toward on of reporting we're top clinical at and which been focused following

an Importantly, deep momentum goal in even including broader SM this which patients applying to to KIT inhibitor. the BLU-XXX, trial is the with HARBOR we're Recently, in milder the learning population. with we carrying our non-advanced expanding DXXXV SM and study, initiated next-generation learning BLU-XXX also and our evaluating of reach disease,

PIONEER As trial patients double to followed updates by of mutant expansion lung HARBOR to study our Phase quarter, dose mutant escalation winds non-small prior engagement be year, includes trial least to We into community. we profile. Later harboring who to next at received year. the our tumors Shifting look the tyrosine plan down, the X/X This clinic global a the BLU-XXX SM one in in with well. we groups our triple cancer, EGFR benefit cell up and ramp with from and EGFR inhibitor, of EGFR targeted patients previously specific mutant the HARBOR second inhibitor we mutation initiated this expertise providing deep expect portion as in BLU-XXX inhibitor. kinase cancer, with lung mutant forward on

we'll single-agent other therapies. activity and For combination agents other rapidly each both in with EGFR-targeted both both and programs evaluate

translational In collaboration first Mike development prolific the with of Anderson, updated our BLU-XXX, and combination E-aberrant to proof-of-concept a continue With cyclin be clinic enter you well enhance homegrown targeting advancing on select inhibitor inhibitor we're drug Yesterday, to It we strategic, all novel designed candidate a a collaboration to the now towards research progress we robust financial ahead. newest this The it turn and MD mono to half expertise I'd our in to proven for in is their by addition, both to cancers. keep to is of year. list advance like updates. scientific program next method expected from identifying tumors known months the in therapy. excited to engine, discuss to CDK announced medicine. responsive data, candidates as over likely to the our selective CDKX

Mike Landsittel

and revenue Christy was driven financial for -- from our included quarter us million, today's discussed by Thanks, collaboration morning And GAVRETO net press global were royalty highlighting Collaboration of by detailed product Becker. just our call this Collaboration and in also shipments Earlier we $XX.X revenue release. I'll second to our strong revenues sales revenue and CStone base of growing commercial as to CStone diversity $XX.X support reported touch the a Total revenues, for positioning on revenue. results $XX.X and few supply future growth. approvals. in global geographic in quarter. broadening included our quarter Roche million the for million in This for highlights primarily partners China. Greater our revenue AYVAKIT revenue

Our and in the total second to drug cost the shipments partners. of to compared We saw our an costs related in expenses first moderately quarter product operating quarter increased of increase to sales XXXX.

expansion. SG&A commercial our addition, expenses In infrastructure increased driven by

have by half, collaboration in the SM, meaningful cash advanced second and foundation that increases expect sufficient Overall, recent that growth. and our from than more a second future wholly-owned we deepening Anchored SM, our to of several over our operating with first to ended milestones, ensuring our resources to which meet will billion have programs the As quarter-over-quarter anticipate commercial increase double we drive expand AYVAKIT the us potential positions the pipeline, of hand SG&A we for the quarter and and company. efforts see of AYVAKIT solid invest with growing promising revenue which revenue nearly investment build in to of series half for then second collaboration medicine financial XXXX a expenses. leading $XXX drug up important our in we us We execution full of in set guidance world's and in on This few advanced strong pipeline as next precision revenue to approval continued $X.X future million clinical the the in quarters with launch the R&D early-stage will we continue a of momentum XXXX, AYVAKIT catalysts year. for we half sales over candidates.

like So questions, Operator? that, Question-and-Answer with now I'd operator the for call over Session turn to to the

Operator

Our line Instructions] first Sachs. you. Richter Thank Salveen from Goldman from [Operator of ahead. the question Please go comes

Salveen Richter

then, with here GAVRETO of the you the Congratulations separately, could Is then, there you next SM XX on thoughts the at the the on overlap the when over is booking what on morning. initial Good sales? launch. the given hematological an mechanics And if Thank takes accounting bolus your there demand just non-advanced for launch? mentioned? total centers opportunity? the are What you. quarter comment Roche advanced And SM trajectory

Christy Rossi

and Great, I I'll then the Christy can This in Mike start. on let chime is accounting.

see really around So SM we're we've seeing been excited interest to launch. the initial feedback advanced and the

thing that, the not, a is of -- is a setting, particularly for It's the seeing potential community what in the among really has future organic early, seeing interest think which notable obviously, those XX growth. exactly of et bolus versus also centers, cetera. but I understanding the we're that yeah, good been certainly lot think I around indicator dynamics so interest

some suggest utilization therapy also that history, that which patients about look interest patients but also time. of of of here, growth indicators experience, I previously coming SM diagnosed prevalent often key they've We're in my amongst a they're ongoing that seeing are to potential growth potentially another seeing emerge seeing think of been broad we that over done. time, and -- newly least and the some we breadth is on the in patients excited therapy breadth given I'm but like advanced at we'll uptake have their interest on treated, clarity and patients, as with over amongst more no demand really prescribing but over we're ongoing driver diagnosed for

greater into patients. Certainly, continues amongst centers the critical centers, be seeing in as both setting, But we broadening to the the are mean from forward centers we be for TV SM So treatment get advanced here. forward we XX that overlap out as a to emerge of critical I allergy The non-advanced we go will those to are to setting going for indications. how look extent.

patients said a the well. common with as and and of in before, disease hematology a I critical play one driver, very mutation e-comm is role much diagnosis non-advanced As can SM

established to these time. up is receive indication accounting. let I'll Maybe on disease of getting advanced that be the for non-advanced us part the comment over certainly Mike with going setting expect a critical to in So centers we

Mike Landsittel

Yes.

our QX, reminder, Roche the record product So of GAVRETO's a end-user as to of forward. or end income section, sales profit our our booking the is, we'll for the is intending will end-user the collaboration one product either sales do or in item It a collaboration transparency sharing position. we'll up Starting revenue QX as then line And the user be flowed show going loss accounting, as mentioned, if what provide if recognized collaboration statement. just in for there U.S. in SG&A. profitable share was in We're to on under the expenses, sales to the revenue we profit continue the is also collaboration. going loss in and the will through that level to the Christy global at true-up

Salveen Richter

you. Thank

Operator

Our line Please Cowen. ahead. from next the question of from Frahm Marc comes go

Marc Frahm

Thanks taking my questions. for One AYVAKIT. to with on Hi. -- on start

there it the the stocking demand? new from or of dose impact strength launch kind in of was Just, is quarter, all the any

Christy Rossi

Yes.

dose XXX advanced already know, very channel. you starting is in had SM the dose, minimal. -- We dose and XXX, So, as the we XXX-milligram XXX,

seen those wasn't to So as there's saw ongoing but haven't in driver strengths a we XX it of what of QX. lot in a the their Patients need be and minimal and that treatment, available. part of utilization XX of channel, huge obviously, we

Marc Frahm

Thanks. then, looking the helpful. And maybe pipeline. to Okay. That's

a of kind think to after monotherapy year to data, RET, for expectation initiating of out data still report to reporting little you able trial. we maybe longer data were a or the for should start of maybe combo reasonable mature EGFR data you do XXX expect you bit Do think before a Just initial that's you wait program? about for the kind you

Jeff Albers

we highlighted, out at we recently entered we'll soon think entered sharing either the and So, guidance having timing. do expectations, clinic. Becker data this we're of every as clinic What specifically wave around new positioned as more a year, lay programs XXXX, in really with of terms the beginning of well now -- or

got feels year advanced had early development And candidates, so, This this year. the fundamentally as in and say, now company in of through last seeing the sort a we across we're candidates me, did, late said that SM a magnitude the than the highlighted, clinical approval pulled the of of sense of it I a it early well out that -- year to we're of quality thought, updates ago, getting those Christy indications, looking terms but different uptake breadth launch better into to giving us with of programs. we'll ride the and year, then Mike series the next these lay that of opportunity.

So we'll but me, is I point of don't where those clinical what, to launches really specifically of the is trials any think guide or the one we're for exciting. at those, breadth of those

Marc Frahm

you. Thank Okay.

Operator

James. question Raymond from go Leone ahead. Dane Our is Please next from

Dane Leone

Hi. launch Thank you for on taking and the questions the updates and all ASM. in congratulations

idea to end give some lines is be lot a appreciated. just you can the as on game terms asked. need on time out that question see again, push us more as much up to following of It Could the then Just of What you you you. Mark think the elaborate the little a think of And I me, maybe which studies, combination bit one here? strategy X into effort. move Phase here? for to clinical of question Thank EGFR would in I

Becker Hewes

Yes.

compounds that. benefit the key I'll the you the these combinations hit to those patients. to The With strategy, nail to head. factor, with providing First take respect overall are

with kinase as lung going both other Combinations, of BLU-XXX and we with inhibitors single are I for exploring those said, and we cancer. single-agent EGFR finish third both, will to of then mutant XXX agent before and We generation explore, start type combinations activity activity. with together, each

either profile different So, about I going We're is learning mutating. experiments how that alone number the patients, of mutation they present the of populations. patient see or there's in on more in different think what a combinations you'll also simultaneously

we will respect as dose the individually. this And -- timing, extent these any the end be -- trial. as have refine the speculate the said, so, as I data update about With thing data the to XXX or we than we compounds our specific we'll the BLU-XXX more give out meal, expect year. rather of strategy escalation piece recently, understand we and to started during the so reported, by to to coming year our next which and combine we've biology previously to enter releasing And there much hesitate periodic Jeff that ability

Jeff Albers

just RET. Mark Jeff. This Maybe them to comparing Dane and combining from and the comments is

data, some get biology where quickly All speculated, be think couple are just of likely travel. encouraging how up us that effective sites to activated first forward-looking there's to signs dose the through patients the escalation on understanding move when are greatest already you're with as fact we'll and benefit. with about The looking dose, to seeing, an lined -- those patients end. the Becker we're to the willing highlighted, of this you'll of statements when Early have sites

we're investigators for more clinic up year. patients markers. So, through of the there nicely. into that the marker potential this moving from And we're running, and there then, one is move the and looking as is, end investigators Becker of by said, first get to can The you XXX, to them those enthusiasm and identify just that are the

I is so together. why together two we're think, tied so, those about collectively optimistic And programs

Dane Leone

all Congratulations Great. Thank you, on guys. the updates.

Operator

comes from from ahead. JMP Securities. Please Reni Benjamin go question next The

Reni Benjamin

the Hi. for well. and guys. Thanks as taking congratulations questions Good morning,

other update the there? the terms in just a kind think, task past well. of at? with thought up know importantly, our I CStone of give test with own NGS, we status talked one look just Can for Thanks. of rest question And own talked of own you as what's about what's patient you application And about testing the world follow-up, of geographies And filing us -- give Chris product? GAVRETO, your a I to Just on strategy regarding as you can the just is what's update PCR, us happening identification. an sort and in as then I with to your happening coming digital XXXX

Jeff Albers

first patient that efforts Roche's about US, Becker little bit the of the a identification. Let part with you then you and take Christy, outside talked

Becker Hewes

Yes.

remember as having EDASA. strategy US the guided GAVRETO and regions, by follow filing, With of right that's they outside under in we've regions other other lined the evaluation review and this at is owned you'll of So, the least shortly Roche respect filed that to to to in they're well European the now. up have a number

Christy Rossi

can patient And thread the run. on then, I pick up and identification

I direction think advanced different what know in let were. I'm have them, around if you might picking you a me been but than asking

Jeff Albers

thought was it GAVRETO. I

Christy Rossi

Are you about GAVRETO asking or...

Reni Benjamin

advanced No, SM, sorry. No. Yes.

So first time.

Christy Rossi

Okay.

something non-advanced FM component. SMA one think and with important really the trying ID are that non-advanced lot in where for is important would important TAB so sensitive in a I disease, advanced of most clearly in levers identify the yes, driving the most is blood-based we've you're But made say accessibility across most critical. most So, And frankly, there, really disease, advanced testing is highly disease to becomes where patients patient diagnosed -- of progress. to advanced I

that among lab and physicians to access really that do much we're So, commercializing easily. capability available be is own so our in going to enable we're the patients so not in, goal testing markets to have can is What it's broadly that assay. trying

few progress terms to the sensitive would working as we of the progress States. patients good that been number available with we available a even nine and highly well through this make Over of of go in develop in large say, accessible I there's I'm test that capability as sure months, are six year. expecting the that ongoing and partners United then it's lab commercially And to to remainder and against the further last

say, we we're better to speaking, there would were in much months see developments a now here. from spot would XX I So expect than generally ago ongoing and even

Reni Benjamin

congrats. and for questions Great. taking the Thanks

Operator

Barclays. Lawson go Peter The Please next question at is ahead. from

Peter Lawson

Hi. the for Thanks taking the update. for question. Thanks

that Just preclinical and through on see what of should venue walk just half? for to if the kind for and you expect XXX potential update the second the we XXX, perhaps in

Becker Hewes

you're assume the in XXX and is talking models. about what preclinical I of So combination XXX

specific identifying that but is where on haven't mutation proper on these we and the complex We working decided models data, we've for gone. are animal a venue, generating models profile

in. partnering are We

We have internal models.

later forward at just for different So this you year should couple a that. looks of look

Peter Lawson

Got so you. much. Thanks

Operator

The from Stanley. Please next Morgan question Lebowitz from ahead. is David go

David Lebowitz

you you you very the with the is of considered Thank in disease? inquiring been patients one ISM of up ISM take to this launch certainly AYVAKIT and for taking there's at the patients these as overall drug past they any much on to of early Are trying it there've PIONEER it actually now In ASM, my elaborated in a physicians -- or might this about inquiries like drug question. been lot the to had ways certainly end sounds them referring run point put be able the trial. get on that patients

Christy Rossi

Sure.

advanced say, and advanced now anecdotally interest the we and diagnosed And HARBOR non-advanced I data both suggests that patients slide, not PIONEER, have the only prescribed we care Certainly, mentioned that the where will down road. seen I their health by SM right So also patients patients being potentially as as that's being provider. the in treated. have interest are in

seeing that with again we're just our engagement So in I synergy think the community. it highlights this

disease, right, is subtyping SM is absolutely complicated. You're one

utilization be early seeing. over that think expect patients we advance on we've what So the I from and may think we data we But to is I in to have differently we're what no with utilization. time heard see anything suggest

David Lebowitz

question. my for Thanks taking

Operator

question from next Kallo from go ahead. is Benjamin The Please Baird.

Benjamin Kallo

Beatty. Benjamin Joel is for This on Hello.

so just us the on you of if the community little interest, potentially for more if from on was And Is provide number much. or questions a demand, repeat of in or few to point could be I of to there's you also might wondering bit a that. then comment AYVAKIT. prescribers. there of a physicians. sense maybe it kind Just you mainly wondering is number clarity demand on of there a more Thank to new is examples able you scripts specific I'm

Christy Rossi

Sure.

like indication one of weeks of I see we would are demand I long point the So duration it's right? these are, majority we guess, patients, think the therapy of at So we patients, we an we duration and care with that that over five this I for the the certainly AYVAKIT, like so, where that new mean, -- transforming this incredible is commenting with which most would really in ways expect is on been expect -- or I've time. given

so seeing certainly your based in the gotten where we we to But that point well through. starting new as first are even barely refills patients And come you on as we've results would calendar, see the in. revenue see to where build coming as

In significant interest early really of which days, that market a a is treatment are community, to launch But me already us again, stakeholders. of launch And we a the I this but what say likely good And community, that be coming the about think saw more broad well. number therapy percent is think from often terms of was immediately changes transformational build paradigm the progress really of for sharing I as and catalyzes continue a the utilization is the from as it's to a we in And I we'll suggests indicator. would almost coming is to rare data. this we disease. the that our

that advanced and assumptions here via be not enabling to in see well to broader as would centers in I both surprised community practices. as of really care so see And

Benjamin Kallo

could I one if then quick And you. follow-up. sneak Thank more Great.

does kind On XX-milligram the any like early speak the that of to dose, the and there? in the comments earlier of or thoughts launch? more about your underutilization XX-milligram that surprising, Is

Christy Rossi

absolutely. Yes,

it's expect, adjustments for SM. to dose I starting the care XXX majority So not individual basis dose being in to but maybe based our milligrams provider, right? XXXX SM patients mean, of advance enable a those expect to strengths appropriate what be XXX there and an I milligrams, milligrams, are on certainly in the underutilized -- we see terms XXX broad a dose of on patient to use wouldn't certainly would we advanced at patients of treated expect

there's I've have far seen -- at that than what we're is would expected. that we nothing so So different

Benjamin Kallo

you Thank much. so it. Got

Operator

ahead. at Schmidt next question Michael from The Please Guggenheim Partners. is go

Michael Schmidt

guys, Hey well. couple my had I program. the on progress inhibitor for CDKX question thanks your congrats and a taking on as

secondly as other inhibition Just perhaps program accelerate potential much. mechanisms one us we the or MD understand think inhibition actually print so about PKMX how example mentioned? help one to cycline with And should PPNE mechanistically, the in amplified for include XXX activity Anderson just setting? Thanks the your then how cases you collaboration in relative that amplified or

Jeff Albers

Thanks Michael.

Anderson. Let with me start MD

is really I to everyone research. knows So, powerhouse with Anderson think translational a MD respect as

and novel XX looking different models combining other mentioned case, Just this understand inhibitors identifying the really uncover patient where including in may in therapeutic mechanisms you And together. those at advantage a two combination is drugs preclinical we're when combinations in sophisticated a the of inhibitors signals number and populations. amazing just that to these CDK identifying of inhibitor And just really CDKX/X beginning Pampa requires how that journey. selective to seen you've development use

on place science other pointed are is dose patients there angle they that, with many so The MD Anderson. that that have the

and understand shelf banks are deeply clear a that that unprecedented we the and identified to understand either endometrial there's to beyond have they and as breadth we involved. or their ability might to TX combination tumor really banks you biology when have of the and such of tumors off the tumor that additional that the the identify that and either the us Blue a cancer and is indications at then ovarian calling or vulnerability So where look they allow investigators really use breast

our expect it. about a This to expect where was happened don't and what UCLA what is we but we excited I'm really CDKX/X identified transformed -- signal activity with what understanding cancer. Pfizer really we expect. And where So enhance breast that

we this subset will the apoptosis these tumors how combine is mechanisms, compound in we're to on. going so we entire career. novel malignancies I futon said, my to of to that parts achievable there's will modalities, that as speculate the it's about we're extent to when novel see. that biology really the activity We're how care really And have can a which I'm compounds amplified be But we net of the most that standard understanding to dependent pathway collaboration cycling focused going excited be of to that respect the CDKX go the posing as into at and other compare. cancers With so looking more other to on about something expecting one relative

Michael Schmidt

Great. Thank you.

Operator

The is Andrew Berens ahead. from next question from Leerink. SVB Please go

Andrew Berens

of said that just new many haven't question for RET any but with And I research new could then you new being are are is after any launch. think as because color now patient patients P&L XX% gross we us adjustments to patients, a change then we of of one or in give you frontline opportunity? Is larger RET treated guys Should was usage, [indiscernible]. on or yet. net a that patients And inhibitor? had it you're starts. you on not is a in Thanks. questions And it seen ASM are see the the what in And on that around and then to seeing A getting you translated the some previously just to as diagnosed anticipated? if RET market any as QX, we sampling percentage was the XX% of expanding couple predominantly ASM. expect the actually on into me wondering I

Christy Rossi

are Those for Great. me. all

And So related. I actually, with are you start asked can questions RET. that all the

over being this sort patient the starts about share. way So of time think total indicator, the that following share patient and is patient then new total first market we

approaches quickly share more obviously market of factor share new total the As the grows.

indications on both in bit months being available. we a so, only of know game the of Lilly prior in advantage town us time that terms a to for And six having had

a seeing new will so for coming. we've but patient catch starts share patient grow, And we as total share new where take time our total gained those to see it we're share up to

growth. revenue robust thinking versus relative certainly mean growth to TRx really last an Tableau So to And time. see of like I of indicator from period think it's that. over continuing about the it's and we're I NRx we've seen for revenue essentially seen what we've

really like to that's focusing point. I to where faster Genentech. we're of growing think I And a with lot the spending we see growing think and market time more your would

are now more being that right of estimate is a maybe inhibitor. and than selective patients that with treated XX%, maybe best a Our potential bit diagnosed then little RET RET

a opportunity and And ID et so patient certainly cetera. to lot the really in of post-COVID and of rebound grow that [Indiscernible] happening there's is we think testing terms to continue

there's to lines Right therapy. And earlier to upon but excited across opportunity get pull-through. seeing that we're patients of now, certainly to So we're see an use diagnosis.

that Certainly, and And in again something is so I were consistent wouldn't AYVAKIT. consistent that focused product the From strategy from strategy access expect a States changes that's on. broad we to we've we're the with dramatic there. been using United distribute the is [Indiscernible] perspective, our where

So against I would system. not expect dramatic as changes

Andrew Berens

Appreciate Thanks. it. Okay.

Operator

comes Arlinda ahead. Our at question from Canaccord. next go Lee Please

Arlinda Lee

taking Great. my of Thanks in -- interested ISM for overlap versus I in was the question. ASM.

PIONEER the mentioned, little then, you increases been the efforts. the DXXXV maybe been inbounds much discuss, ISM any able the if a about to HARBOR I'm been think you've -- you. do key there on And You you've education how And is ISM? how can there much you testing? bit overlap maybe Thank with talk if seeing if can population? in into and you Have you centers. get disease wondering is ASM

Christy Rossi

Sure.

as point -- for think a earlier, half think out those enrollment again to for seeing we patients patients States. being but whether in real we play United time patients. I as the of that, identified, studies engaging Certainly, goal be PIONEER key They -- a facilitate then also I non-advanced as role see where SM is being that are lot or our I we're clinical centers And patients, in treatment. non-advanced XX in also where the HARBOR. in shared patients said we're key So SM we're with treated the seeing advanced are that sites who eventually interested about this advance certainly at

into we So But we becomes more we're think -- important a generally, think going XX and many broader patients they following a on be allergy as into I role good the I play in call foothold these nonevent on I And centers up of a as is market ride still then will more us as said the -- that get interest. market. point. help be as ISM certainly really to will a sort diagnose for

Arlinda Lee

main guys way you a of then or kind patient there And for that the track identification? Great. -- the for to mentioned DXXXV that a of levers you is as bottleneck was testing one

Christy Rossi

Yeah.

-- compare where mean, something if who get are with -- goal the there think to subtle the is I difference GAVRETO this difference over a mutation. diagnosed cancer at be I even time. will I So the say we for appropriately to think a looking lung I patients we're tested is being here,

a our diagnosis, we mutation, of the really patients. specific Here, as not kind particularly facilitating label is obviously to see non-advanced increased to the but key being testing for

So it's the just obviously We're market commercially. early. in

non-advanced patients over have see And number that that play the in the of I growth something sense way is think and a think we we'll I time. see. really certainly out we'll of identify So can

place we development when that's anticipated education, terms focus now of and cetera to approval will that disease we market a et have continue a And so in between there.

Arlinda Lee

very much. you Thank Great.

Operator

further There at no questions this are time.

Albers. to call the Mr. hand I'll back So

Jeff Albers

us time support a soon. thank join Have and look day. taking Thanks, your the we Medicines. of to you And operator, all again continued to for Blueprint forward updating great Bye-bye. for and today you

Operator

today's concludes conference call. joining. for This Thank all you

now disconnect. may You